Our findings suggest that adipose tissue progenitor cells cooperate in driving progression and metastatic spread of breast cancer.
Introduction
There is increasing evidence that obesity, an excess accumulation of adipose tissue occurring in mammalians when caloric intake exceeds energy expenditure, is associated with an increased frequency and morbidity of several types of neoplastic diseases, including postmenopausal breast cancer (reviewed in 1). Disruption of the energy homeostasis results in obesity, inflammation and alterations of adipokine signalling that may foster initiation and progression of cancer (2) (3) (4) . Preclinical studies have suggested that differentiated cells of the white adipose tissue (WAT) and WAT-resident progenitors may also promote cancer growth and metastasis. We described that CD45-CD34+
progenitors from human white adipose tissue (WAT) may promote breast cancer growth and metastases in preclinical models (5). Other recent studies, some of which based on endogenous WAT expressing a transgenic reporter, demonstrated a significant level of adipose cell contribution to tumor composition (6-10). However, WAT contains several distinct populations of progenitors, and these data were obtained using crude or mixed cell populations. We therefore decided to purify by sorting the two quantitatively most relevant populations of WAT progenitors (endothelial cells, ECs, and adipose stromal cells, ASCs) and to investigate in vitro and in vivo their role in several orthotopic models of local and metastatic breast cancer. 
Materials and Methods

WAT collection and flow cytometry
As we previously described (5, 11), human WAT (>150 samples) was obtained after the signature of an informed consent from women undergoing breast reconstruction. In brief, samples were centrifuged at 1200g to remove erythrocytes and leukocytes and subsequently digested in HBSS (Gibco, UK) containing 2 mg/mL of collagenase type I (Sigma Aldrich, St. Louis, MO, USA) and 3.5% bovine serum albumin (BSA; Sigma Aldrich) at 37°C with constant shaking for 120 minutes. The digestion was blocked with RPMI 1640 supplemented by 20% FBS (Euroclone, Italy), and a cell pellet was obtained by centrifugation at 1200g for 10 minutes at 4°C.
The cell suspension was then processed through a 100 μm mesh filter to remove undigested tissue and washed twice with incubation buffer (PBS with 2 mM EDTA and 0.5% BSA), working always on ice. An aliquot of these cells was labeled for flow cytometry analysis. At least 500.000 total cells per sample were acquired on a flow cytometer equipped with 3 laser (Navios, Beckman Coulter, Pasadena, CA, USA) and analysis was performed by a KALUZA software (Beckman Coulter), after selection of DNA+ (Syto16+) and viable (7-AAD-) cells. Analysis gates were set with the aid of ''fluorescence minus outcomes'' isotype controls. Monoclonal antibodies used in the study are described in Supplementary Table 1. Hematopoietic CD45-CD34+ stem cells, ECs and ASCs were measured in the BM and in the PB by flow cytometry as described above in >30 healthy volunteers and in cancer patients (who signed an informed consent) before and after stem cell mobilization by G-CSF, cyclophosphamide+G-CSF or AMD3100+G-CSF. Mice were anesthetized with 2.5% 2-2-2-tribromoethanol (Avertin; Sigma Aldrich), laid on their backs, and injected with 20 µL of cell suspension in Matrigel directly in the fourth mammary fad pad through the nipple with a Hamilton syringe.
Tumor growth was monitored at least once a week using digital callipers, and tumor One month after cell injection, mice were sacrificed by carbon dioxide inhalation. Right axillary lymph node and lung tissue were removed.
To confirm the presence of metastases, sections were cut and stained with hematoxylin and eosin (H&E) as previously described (5).
In brief, for detection of metastases, the axillary lymph node and lungs were fixed in 4%
phosphate-buffered formalin and embedded in paraffin. Five-micron sections of the entire lungs and lymph node were made, and slides were counterstained with H&E for the detection of metastases. The Scan Scope XT device and the Aperio Digital pathology system software were used for the analysis.
RT-PCR and expression analysis
RNA isolations from ASCs and ECs of 7 different patients were carried out using QIAmp RNABlood Mini Kit (Qiagen, the Netherlands), and cDNAs were generated from 40 ng of RNA using the high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA); quantitative real-time PCR (qRT-PCR) was carried out with an ABI Prism 700 platform as previously described (Martin-padura et al., 2012) using primers and probes from the TaqMan Gene Expression Assay.
Research. For microarray analysis, synthesis of labeled targets, array hybridization (Affymetrix GeneChip Gene ST 1.0 Human array; Affymetrix, santa Clara, CA, USA), staining, and scanning were carried out according to Affymetrix standard protocols, starting from 500 ng of total RNA. Duplicate microarrays were hybridized with each DNA sample. The MAS5 algorithm was used to determine the expression levels of mRNAs; the absolute analysis was carried out using default parameters and scaling factor 500. Report files were extracted for each microarray chip, and performance of labeled target was evaluated on the basis of several values (e.g., scaling factor, background and noise values, percentage of present calls, average signal value). Results were confirmed by qRT-PCR.
Immunofluorescence and Confocal Microscopy Analysis
To assess the effects of ASCs and ECs on tumor angiogenesis, immunofluorescence analysis of CD31, α-SMA (1A4, Sigma Aldrich) and CENP-A (ab13939, AbCam, Boston, MA, USA) was performed on 5 μm-thick FFPE sections obtained after sacrifice of mice.
Sections were collected on superfrost plus slides (Thermo Scientific, Waltham, MA, USA).
After deparaffination and hydratation antigen retrieval was accomplished by heating (at 97°C) in 10 mM sodium citrate buffer/0.05% Tween 20 (Sigma-Aldrich) (pH 6.0) for 30 min. Images were acquired using a Leica TCS SP5 confocal microscope, and sequential Zstacks were performed using 40X (1.4NA) oil immersion objective.
For confocal Imaging, all the z-stacks were collected on a Lieca SP5 II confocal microscope (Leica Microsystems, Exton, PA) using a 40X oil immersion objective with a numerical aperture of 1.3 at zoom 1.7. Fluorochromes were excited using a 405-nm diode laser for Dapi, an argon 488 laser for Alexa 488 and a 561 diode laser for Alexa 555.
Detector slits were configured in order to minimize the cross talk between channels and to maximize the signal arising from the sample: PMT1, 407-485 nm (Dapi); PMT2, 492-556 nm (Alexa 488); PMT3, 579-684 nm (Alexa 555); the cross talk is also limited by the fact that the stacks were collected in "between frame mode": i.e. the blue and red fluorescence (spectrally well separated) are collected simultaneously while the green one by itself. EBM2. After one weeks of coculture, without any changing of medium, the cells in both chambers were collected in RTL buffer (Qiagen, the Netherlands) for RNA extraction. RNA isolation was carried out using QIAmp RNA Blood Mini Kit (Qiagen), and cDNA was generated from 1ug of RNA using the high-capacity cDNA reverse transcription kit (Applied Biosystems); quantitative real-time PCR (qRT-PCR) was carried out with an ABI Prism 700 platform using the EMT PCR Array following the manufacture instruction. The analysis were performed with RT² Profiler™ PCR Array Data Analysis Web base.
Time lapse assays
WAT-derived human cells were plated in EGM-2 medium (Lonza) 5 days before the experiment, in a 6-well plates precoated with rat tail collagen. Plates were placed in a 37°C, 5% CO 2 humidified incubator. Adherent cells were trypsin detached, washed once, and resuspended in EBM-2 medium (Lonza) without growth factors to a final volume of 80 µL of 50.000 WAT-cells and 50.000 MDA-MB-436 cells.
Selected growth factors (HGF 100ng/ml, insulin 10µg/ml, PDGF 10ng/ml, EGF 100ng/ml) were polymerized in highly concentrated 3D type I collagen gels (10.21 mg/ml); on top of these gels the suspension of MDA-MB-436 cells alone or in the presence of WAT-derived human cells was seeded and allowed to invade 3D collagen matrices as previously described (12) . The invasive migration of tumor cells was then monitored by taking pictures every 5 minutes for 48 hours.
Time lapse imaging of cell migration was performed on an Eclipse TE2000-E inverted full motorized microscope (Nikon, Japan) equipped with an incubation chamber (OKOlab) for temperature and CO 2 control. Movies were acquired by a Cascade II 512 CCD camera (Photometrics, Japan) controlled by Metamorph Software (Molecular Devices, Sunnyvale, CA, USA) using a 10×/0.30 NA magnification objective. Tracking of cells was performed using the "Manual Tracking" plugin distributed with ImageJ software. Single cells were followed and the rate of invasion, the speed of motion, the directionality and the distance covered by tumoral cells were measured under the different experimental conditions.
Renal capsule invasion assay
As previously described by Walter et al. (13) 
Results
Ultrastructural and molecular characterization of CD45-CD34+CD31+CD13-CCRL2+ (WAT-ECs) and CD45-CD34+CD31-CD13+CD140b+ (WAT-ASC) progenitors
As shown in Fig. 1 , the multiparametric flow cytometry investigation of non-hematopoietic (ie CD45-) cells present in human WAT showed the presence of three major cell populations: a) CD34+CD31+CD13-CCRL2+ ECs, b) CD34+CD31-CD13+CD140b+
ASCs, and c) mature CD34-CD13+CD140b+ pericyte/fibroblasts. In >150 human WAT samples collected and processed as we previously described (5, 11), the percentage of non hematopoietic (CD45-cells) was 55±14%, and among those ECs, ASCs and mature pericyte/fibroblasts were 50±14, 42±16 and 8±7%, respectively.
As shown in Fig. 2 , the very large majority of sorted human WAT CD34+ ECs were small, undifferentiated progenitors ( Fig. 2A) . These findings were consistent with previous data from Zimmerlin et al (14) indicating that in human WAT mature endothelial cells are not CD34+. In fact, we found by flow cytometry a small population (<5% of all WAT cells) of CD45-DNA(Syto)+CD31+CD34-cells that were likely mature endothelial cells.
Among sorted ECs, a few cells showed initial hallmarks of endothelial differentiation such as Weibel Palade microtubulated bodies (Fig 2 B-C ) and a few formed microcapillaries (Fig. 2D) . At the present time, we believe WAT CD45-CD34+CD31+ ECs are a mixed population of endothelial cells enriched for endothelial progenitors. When investigated at the molecular level (data on file at www.ncbi.nlm.nih.gov/geo , NCBI tracking system #16724781), sorted ECs (>96% purity) overexpressed endothelial-specific genes such as VE-Cadherin, Claudin 5, Tie-2, VEGFR1,2,3, ICAM-2, Dll4, and 16 out of the 18 genes recently discovered in developing endothelial cells (15) . Sorted ECs, but not ASC, generated VE-Caherin-expressing endothelial cells in vivo and in vitro (Fig. 1D-F Array and confirmatory quantitative PCR data indicated that purified ECs expressed 3-16 times more CCRL2 mRNA compared to purified ASCs.
As shown in Fig. 3A , the large majority of human WAT ASCs were small, undifferentiated mesenchymal progenitors. A few of these cells showed hallmarks of initial adipose cell differentiation such as lipid droplets (Fig. 3B-E) . Gene expression studies indicated that purified ASCs overexpressed perivascular cell genes such as Endosialin, Adam12, PDGF receptors, TGFbeta, CD44 and RUNX1. Decreasing levels of CD34 expression among some ASCs (Supplementary Fig. 1 ) suggested that WAT CD45-CD34-CD140b+ pericyte/fibroblasts might derive from CD45-CD34+CD140b+ ASC progenitors. Further studies are ongoing to validate the hypothesis that CD34-pericytes are generated by
CD34+ ASCs
When collected form human WAT, more than 98% of ECs and ASCs were Ki-67 negative and in 2N (data not shown). Levels of CD34 gene expression were similar in WAT ECs and ASCs.
WAT-ECs and ASC have different trafficking potential
We enumerated ECs and ASCs in human lymph nodes (LNs), peripheral blood (PB) and bone marrow (BM) by 10-color multiparametric flow cytometry following a validated approach with a sensitivity of 10 -4 (5, 11, 16). Since LNs are rich in high endothelial venule (HEV) cells (17), we also investigated the HEV-specific MECA 79 antigen to discriminate between HEV cells and ECs ( Supplementary Fig. 2 ). As shown in Fig. 4A -B, human LNs were rich in ECs, but ASCs were <1%.
In human BM and PB, ECs with a phenotype similar to WAT ECs were always <0.1/µL and ASCs were always <0.1/µL. These data suggest that WAT ECs and ASCs are extremely rare in human BM and are not likely to traffic to PB in healthy subjects.
Research. 
We measured the number of cells with a phenotype similar to WAT ECs (CD45-CD34+CD31+CCRL2+ cells) and ASCs (CD45-CD34+CD31-CD13+CD140b+ cells) in the PB of >30 healthy subjects and in the PB of 15 cancer patients before and after several different procedures for the mobilization of hematopoietic stem cells for autologous transplant (Fig 4C) . CD45+CD34+ hematopoietic progenitors, ECs and ASCs/µL blood were similar in healthy subjects and in cancer patients before mobilization. EC count (always <0.1/µL PB before mobilization), was increased to 2-800/mL 5 days after G-CSF administration. The addition of chemotherapy and/or the CXCR4 inhibitor AMD3100 did not increase EC mobilization in the PB.
At variance with ECs, G-CSF administration was associated only to a minimal mobilization of ASCs (from <0.1/µL PB before mobilization to a peak of 10-70/mL PB), and this mobilization was observed only in a minority (3 out of 15) of the patients investigated. Also in the case of ASCs, the addition of chemotherapy and/or AMD3100 to G-CSF did not increase ASC mobilization in the PB.
Human WAT ECs, when injected in murine mammary fat pads, generated vascular structures ( Fig. 5A-B) , migrated toward LNs (Fig. 5C ) and to contra-lateral nascent breast cancer lesions where they generated new vessels (Fig. 5D) . Conversely, human ASCs did not generate vascular structures and did not migrate (data not shown).
WAT-ECs and ASC have different roles in promoting breast cancer angiogenesis, growth and metastases
As shown in 
WAT cells were significantly less effective in increasing local tumor growth. These data suggest that in these models the large majority (if not all) of the activity of WAT was due to cells included in the CD34+ fraction. The co-administration of purified ECs or ASCs increased tumor volumes, but in both models purified ASCs were slightly more efficient than purified ECs in promoting local tumor growth (Fig. 6A-B) .
The role of human WAT CD34+ cells, ECs and ASCs was then studied in a preclinical orthotopic model of breast cancer metastatic spreading in the lung after mastectomy (5).
As shown in Fig. 6C , the co-injection of CD34+ cells significantly increased the number of lung metastases in mice over controls and mice injected with human CD34-WAT cells. were co-injected with tumors, we observed human CD31+ endothelial cells (but not human CD140b+ pericytes) participating into nascent functional tumor vasculature in the first 2-3 weeks after injection (Fig. 6D) . Conversely, when human ASCs (and not ECs) were coinjected with tumors, we observed human CD140b+ pericytes (but not human CD31+ endothelial cells) participating into tumor vasculature for more than one month after injection (Fig. 6E) . Fig. 6 ).
WAT-ECs and ASC cooperate in inducing breast cancer cell migration
In time lapse culture studies (Fig. 7) , WAT CD34+ cells (but not CD34-cells) induced a significant increase in breast cancer cell migration toward chemoattractants such as HGF, show an increased risk of recurrence of local events when compared to controls (11, (20) (21) . We observed in WAT ECs an overexpression of CCRL2 ( Fig. 1 and Supplementary Fig.   8 ). This molecule has been described as a receptor for the chemokine/adipokine chemerin, involved in autocrine and paracrine signaling for adipocyte differentiation, and found to stimulate chemotaxis of dendritic cells and macrophages to the site of inflammation (25) . Chemerin was overexpressed in WAT ASCs when compared to ECs, and we are currently studying whether targeting CCRL2 and/or chemerin might impair EC trafficking towards WAT and/or the tumor and metastases promoting role of ECs and 
